Conclusions
In summary, based on our findings, we think that the outlook on developing and evaluating new drugs for pregnant women may not be bright, unless there are appropriate policies and measures. However, the results of this study are not too frustrating either: In China, there are still studies conducted in pregnant women at a certain frequency by sponsors and clinical institutions. More attention should be paid to the use of marketed drugs in pregnant women and give priority to the study on the PK of pregnant women.